Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Total Bond Market Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Vanguard Total Bond Market Index Fund ETF trades at $72.7. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BND | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $75.17 |
52-Week Low | $10.24 | $72.45 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BND trades at $72.85, down 0.36% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at oversold levels. Recent dividend distributions of $0.24-$0.25 provide income appeal, while financial media highlights BND's role in diversified portfolios and compares it favorably against peers on yield and cost metrics.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. BND offers broad bond market exposure for income-focused investors, though duration risk persists if rates rise. Current levels may appeal to long-term investors seeking steady income with institutional quality diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
